Advertisement

Langenbeck's Archives of Surgery

, Volume 390, Issue 2, pp 94–103 | Cite as

Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?

  • H. G. Smeenk
  • T. C. K. Tran
  • J. Erdmann
  • C. H. J. van Eijck
  • J. JeekelEmail author
Current Concepts in Clinical Surgery

Abstract

Surgery for pancreatic cancer offers a low success rate but it provides the only likelihood of cure. Modern series show that, in experienced hands, the standard Whipple procedure is associated with a 5-year survival of 10%–20%, with a perioperative mortality rate of less than 5%. Most patients, however, will develop recurrent disease within 2 years after curative treatment. This occurs, usually, either at the site of resection or in the liver. This suggests the presence of micrometastases at the time of operation. Negative lymph nodes are the strongest predictor for long-term survival. Other predictors for a favourable outcome are tumour size, radical surgery and a histopathologically well-differentiated tumour. Adjuvant therapy has, so far, shown only modest results, with 5FU chemotherapy, to date, the only proven agent able to increase survival. Nowadays, the choice of therapy should be based on histopathological assessment of the tumour. Knowledge of the molecular basis of pancreatic cancer has led to various discoveries concerning its character and type. Well-known examples of genetic mutations in adenocarcinoma of the pancreas are k-ras, p53, p16, DPC4. Use of molecular diagnostics and markers in the assessment of tumour biology may, in future, reveal important subtypes of this type of tumour and may possibly predict the response to adjuvant therapy. Defining the subtypes of pancreatic cancer will, hopefully, lead to target-specific, less toxic and finally more effective therapies. Long-term survival is observed in only a very small group of patients, contradicting the published actuarial survival rates of 10%–45%. Assessment of clinical benefit from surgery and adjuvant therapy should, therefore, not only be based on actuarial survival but also on progression-free survival, actual survival, median survival and quality of life (QOL) indicators. Survival in surgical series is usually calculated by actuarial methods. If there is no information on the total number of patients and the number of actual survivors, and no clear definition of the subset of patients, actuarial survival curves can prove to be misleading. Proper assessment of QOL after surgery and adjuvant therapy is of the utmost importance, as improvements in survival rates have, so far, proved to be disappointing.

Keywords

Pancreatic cancer Adenocarcinoma Prognostic factors Survival 

References

  1. 1.
    Kausch W (1912) Das Carcinom der papilla duodeni und seine radikale Entfernung. Beitr Z Clin Chir 78:439–486Google Scholar
  2. 2.
    Whipple AO, Parsons WB, Mullins CR (1935) Treatment of carcinoma of the ampulla of Vater. Ann Surg 102:763–779Google Scholar
  3. 3.
    Janes RH Jr, Niederhuber JE, Chmiel JS, Winchester DP, Ocwieja KC, Karnell JH, Clive RE, Menck HR (1996) National patterns of care for pancreatic cancer. Results of a survey by the Commission on Cancer. Ann Surg 223:261–272CrossRefPubMedGoogle Scholar
  4. 4.
    American Cancer Society (2000) Statistics, cancer facts and figures 2000Google Scholar
  5. 5.
    Birk D, Fortnagel G, Formentini A, Beger HG (1998) Small carcinoma of the pancreas. Factors of prognostic relevance. J Hepatobiliary Pancreat Surg 5:450–454CrossRefPubMedGoogle Scholar
  6. 6.
    Cubilla AL, Fortner J, Fitzgerald PJ (1978) Lymph node involvement in carcinoma of the head of the pancreas area. Cancer 41:880–887PubMedGoogle Scholar
  7. 7.
    Ishikawa O, Ohhigashi H, Sasaki Y, Kabuto T, Fukuda I, Furukawa H, Imaoka S, Iwanaga T (1988) Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 208:215–220PubMedGoogle Scholar
  8. 8.
    Nagakawa T, Kayahara M, Ohta T, Ueno K, Konishi I, Miyazaki I (1991) Patterns of neural and plexus invasion of human pancreatic cancer and experimental cancer. Int J Pancreatol 10:113–119PubMedGoogle Scholar
  9. 9.
    Satake K, Nishiwaki H, Yokomatsu H, Kawazoe Y, Kim K, Haku A, Umeyama K, Miyazaki I (1992) Surgical curability and prognosis for standard versus extended resection for T1 carcinoma of the pancreas. Surg Gynecol Obstet 175:259–265PubMedGoogle Scholar
  10. 10.
    Balcom JH, Rattner DW, Warshaw AL, Chang Y, Fernandez-del Castillo C (2001) Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg 136:391–398CrossRefPubMedGoogle Scholar
  11. 11.
    Cameron JL, Pitt HA, Yeo CJ, Lillemoe KD, Kaufman HS, Coleman J (1993) One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg 217:430–435PubMedGoogle Scholar
  12. 12.
    Crist DW, Sitzmann JV, Cameron JL (1987) Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg 206:358–365PubMedGoogle Scholar
  13. 13.
    Geer RJ, Brennan MF (1993) Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 165:68–72PubMedGoogle Scholar
  14. 14.
    Millikan KW, Deziel DJ, Silverstein JC, Kanjo TM, Christein JD, Doolas A, Prinz RA (1999) Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 65:618–623PubMedGoogle Scholar
  15. 15.
    Pellegrini CA, Heck CF, Raper S, Way LW (1989) An analysis of the reduced morbidity and mortality rates after pancreaticoduodenectomy. Arch Surg 124:778–781PubMedGoogle Scholar
  16. 16.
    Sohn TA, Campbell KA, Pitt HA, Sauter PK, Coleman JA, Lillemo KD, Yeo CJ, Cameron JL (2000) Quality of life and long-term survival after surgery for chronic pancreatitis. J Gastrointest Surg 4:355–364CrossRefPubMedGoogle Scholar
  17. 17.
    Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567–579CrossRefPubMedGoogle Scholar
  18. 18.
    Trede M, Schwall G, Saeger HD (1990) Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 211:447–458PubMedGoogle Scholar
  19. 19.
    Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, Dooley WC, Coleman J, Pitt HA (1995) Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 221:721–731PubMedGoogle Scholar
  20. 20.
    Birkmeyer JD, Warshaw AL, Finlayson SR, Grove MR, Tosteson AN (1999) Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery 126:178–183CrossRefPubMedGoogle Scholar
  21. 21.
    Birkmeyer JD, Siewers AE, Finlayson EV, Stukel TA, Lucas FL, Batista I, Welch HG, Wennberg DE (2002) Hospital volume and surgical mortality in the United States. N Engl J Med 346:1128–1137CrossRefPubMedGoogle Scholar
  22. 22.
    Meyer W, Jurowich C, Reichel M, Steinhauser B, Wunsch PH, Gebhardt C (2000) Pathomorphological and histological prognostic factors in curatively resected ductal adenocarcinoma of the pancreas. Surg Today 30:582–587CrossRefPubMedGoogle Scholar
  23. 23.
    Yeo CJ, Cameron JL (1994) Arguments against radical (extended) resection for adenocarcinoma of the pancreas. Adv Surg 27:273–284PubMedGoogle Scholar
  24. 24.
    Pedrazzoli S, DiCarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C, Kloppel G, Dhaene K, Michelassi F (1998) Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy study group. Ann Surg 228:508–517CrossRefPubMedGoogle Scholar
  25. 25.
    Yeo CJ, Cameron JL, Sohn TA, Coleman J, Sauter PK, Hruban RH, Pitt HA, Lillemoe KD (1999) Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg 229:613–622CrossRefPubMedGoogle Scholar
  26. 26.
    Klinkenbijl JH, van der Schelling GP, Hop WC, van Pel R, Bruining HA, Jeekel J (1992) The advantages of pylorus-preserving pancreatoduodenectomy in malignant disease of the pancreas and periampullary region. Ann Surg 216:142–145PubMedGoogle Scholar
  27. 27.
    Cameron JL, Crist DW, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ, Coleman J (1991) Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 161:120–124PubMedGoogle Scholar
  28. 28.
    Lin PW, Lin YJ (1999) Prospective randomized comparison between pylorus-preserving and standard pancreaticoduodenectomy. Br J Surg 86:603–607CrossRefPubMedGoogle Scholar
  29. 29.
    Seiler CA, Wagner M, Schaller B, Sadowski C, Kulli C, Buchler MW (2000) Pylorus preserving or classical Whipple operation in tumors. Initial clinical results of a prospective randomized study. Swiss Surg 6:275–282PubMedGoogle Scholar
  30. 30.
    Tran TCK, Smeenk HG, Eijck CHJ, Kazemier G, Hop W, Greve JW, Terpstra OT, Zijlstra J, Klinkert P, Jeekel J (2004) Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure; a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors. Ann Surg (accepted)Google Scholar
  31. 31.
    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics. CA Cancer J Clin 53:5–26Google Scholar
  32. 32.
    Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358:1576–1585CrossRefPubMedGoogle Scholar
  33. 33.
    Tran K, Van Eijck C, Di Carlo V, Hop WC, Zerbi A, Balzano G, Jeekel H (2002) Occlusion of the pancreatic duct versus pancreaticojejunostomy: a prospective randomized trial. Ann Surg 236:422–428CrossRefPubMedGoogle Scholar
  34. 34.
    Amikura K, Kobari M, Matsuno S (1995) The time of occurrence of liver metastasis in carcinoma of the pancreas. Int J Pancreatol 17:139–146PubMedGoogle Scholar
  35. 35.
    Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RE, Evans RG (1990) Patterns of failure after curative resection of pancreatic carcinoma. Cancer 66:56–61PubMedGoogle Scholar
  36. 36.
    Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I (1993) An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer 72:2118–2123PubMedGoogle Scholar
  37. 37.
    Sperti C, Pasquali C, Piccoli A, Pedrazzoli S (1997) Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 21:195–200CrossRefPubMedGoogle Scholar
  38. 38.
    Takahashi S, Ogata Y, Miyazaki H, Maeda D, Murai S, Yamataka K, Tsuzuki T (1995) Aggressive surgery for pancreatic duct cell cancer: feasibility, validity, limitations. World J Surg 19:653–659PubMedGoogle Scholar
  39. 39.
    Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M (2003) Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 27:324–329CrossRefPubMedGoogle Scholar
  40. 40.
    Kobari M, Matsuno S (1998) Staging systems for pancreatic cancer: differences between the Japanese and UICC systems. J Hepatobiliary Pancreat Surg 5:121–127CrossRefPubMedGoogle Scholar
  41. 41.
    Kalser MH, Ellenberg SS (1985) Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899–903PubMedGoogle Scholar
  42. 42.
    Bakkevold KE, Arnesjo B, Dahl O, Kambestad B (1993) Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater—results of a controlled, prospective, randomised multicentre study. Eur J Cancer 29A:698–703PubMedGoogle Scholar
  43. 43.
    Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman J, Sauter PK, Pitt HA, Lillemoe KD, Cameron JL (1997) Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225:621–633CrossRefPubMedGoogle Scholar
  44. 44.
    Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230:776–782CrossRefPubMedGoogle Scholar
  45. 45.
    Beger HG, Gansauge F, Buchler MW, Link KH (1999) Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer: significant reduction in occurrence of liver metastasis. World J Surg 23:946–949CrossRefPubMedGoogle Scholar
  46. 46.
    Link KH, Gansauge F, Rilinger N, Beger HG (1997) Celiac artery adjuvant chemotherapy. Results of a prospective trial. Int J Pancreatol 21:65–69PubMedGoogle Scholar
  47. 47.
    Lygidakis NJ, Sgourakis G, Georgia D, Vlachos L, Raptis S (2002) Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease: a prospective randomized study. Ann Surg 236:806–813CrossRefPubMedGoogle Scholar
  48. 48.
    Aristu J, Canon R, Pardo F, Martinez-Monge R, Martin-Algarra S, Manuel, Ordonez J, Villafranca E, Moreno M, Cambeiro M, Azinovic I (2003) Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer. Am J Clin Oncol 26:30–36Google Scholar
  49. 49.
    Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB (2001) Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8:123–132CrossRefPubMedGoogle Scholar
  50. 50.
    Jeekel J, Treurniet-Donker AD (1991) Treatment perspectives in locally advanced unresectable pancreatic cancer. Br J Surg 78:1332–1334PubMedGoogle Scholar
  51. 51.
    Mehta VK, Fisher G, Ford JA, Poen JC, Vierra MA, Oberhelman H, Niederhuber J, Bastidas JA (2001) Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg 5:27–35CrossRefPubMedGoogle Scholar
  52. 52.
    Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L (2000) Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 89:314–327CrossRefPubMedGoogle Scholar
  53. 53.
    Li CP, Chao Y, Chi KH, Chan WK, Teng HC, Lee RC, Chang FY, Lee SD, Yen SH (2003) Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 57:98–104CrossRefPubMedGoogle Scholar
  54. 54.
    Ducreux M, Rougier P, Pignon JP, Douillard JY, Seitz JF, Bugat R, Bosset JF, Merouche Y, Raoul JL, Ychou M, Adenis A, Berthault-Cvitkovic F, Luboinski M (2002) A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 13:1185–1191Google Scholar
  55. 55.
    El Rayes BF, Zalupski MM, Shields AF, Vaishampayan U, Heilbrun LK, Jain V, Adsay V, Day J, Philip PA (2003) Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol 21:2920–2925CrossRefPubMedGoogle Scholar
  56. 56.
    Philip PA (2002) Gemcitabine and platinum combinations in pancreatic cancer. Cancer 95:908–911CrossRefPubMedGoogle Scholar
  57. 57.
    Van Laethem JL, Demols A, Gay F, Closon MT, Collette M, Polus M, Houbiers G, Gastelblum P, Gelin M, Houtte PV, Closset J (2003) Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study. Int J Radiat Oncol Biol Phys 56:974–980CrossRefPubMedGoogle Scholar
  58. 58.
    Lynch HT, Brand RE, Deters CA, Shaw TG, Lynch JF (2001) Hereditary pancreatic cancer. Pancreatology 1:466–471CrossRefPubMedGoogle Scholar
  59. 59.
    Schneider G, Schmid RM (2003) Genetic alterations in pancreatic carcinoma. Mol Cancer 2:15CrossRefPubMedGoogle Scholar
  60. 60.
    Kawesha A, Ghaneh P, Andren-Sandberg A, Ograed D, Skar R, Dawiskiba S, Evans JD, Campbell F, Lemoine N, Neoptolemos JP (2000) K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 89:469–474CrossRefPubMedGoogle Scholar
  61. 61.
    Cowgill SM, Muscarella P (2003) The genetics of pancreatic cancer. Am J Surg 186:279–286CrossRefPubMedGoogle Scholar
  62. 62.
    Ghaneh P, Kawesha A, Evans JD, Neoptolemos JP (2002) Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg 9:1–11CrossRefPubMedGoogle Scholar
  63. 63.
    Dergham ST, Dugan MC, Sarkar FH, Vaitkevicius VK (1998) Molecular alterations associated with improved survival in pancreatic cancer patients treated with radiation or chemotherapy. J Hepatobiliary Pancreat Surg 5:269–272CrossRefPubMedGoogle Scholar
  64. 64.
    Li J, Kleeff J, Guo J, Fischer L, Giese N, Buchler MW, Friess H (2003) Effects of STI571 (Gleevec) on pancreatic cancer cell growth. Mol Cancer 2:32CrossRefPubMedGoogle Scholar
  65. 65.
    Ciardiello F, Tortora G (2003) Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 39:1348–1354CrossRefPubMedGoogle Scholar
  66. 66.
    Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316PubMedGoogle Scholar
  67. 67.
    Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS, Sweeney CJ (2000) Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 21:139–146PubMedGoogle Scholar
  68. 68.
    Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ (2000) Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 60:5767–5772PubMedGoogle Scholar
  69. 69.
    Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Legge F, Maggiano N, Gessi M, Mancuso S, Ranelletti FO, Scambia G (2002) Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 13:1205–1211Google Scholar
  70. 70.
    Raju U, Nakata E, Yang P, Newman RA, Ang KK, Milas L (2002) In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. Int J Radiat Oncol Biol Phys 54:886–894CrossRefPubMedGoogle Scholar
  71. 71.
    Blanke CD (2002) Celecoxib with chemotherapy in colorectal cancer. Oncology (Huntingt) 16:17–21Google Scholar
  72. 72.
    Ribas A, Butterfield LH, Glaspy JA, Economou JS (2003) Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 21:2415–2432CrossRefPubMedGoogle Scholar
  73. 73.
    Kim JA (2003) Targeted therapies for the treatment of cancer. Am J Surg 186:264–268CrossRefPubMedGoogle Scholar
  74. 74.
    Gudjonsson B (2002) Survival statistics gone awry: pancreatic cancer, a case in point. J Clin Gastroenterol 35:180–184CrossRefPubMedGoogle Scholar
  75. 75.
    Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R (1999) An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 85:1261–1268PubMedGoogle Scholar
  76. 76.
    Glimelius B (1998) Chemotherapy in the treatment of cancer of the pancreas. J Hepatobiliary Pancreat Surg 5:235–241CrossRefPubMedGoogle Scholar
  77. 77.
    Conlon KC, Klimstra DS, Brennan MF (1996) Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 223:273–279CrossRefPubMedGoogle Scholar
  78. 78.
    Hirata K, Sato T, Mukaiya M, Yamashiro K, Kimura M, Sasaki K, Denno R (1997) Results of 1001 pancreatic resections for invasive ductal adenocarcinoma of the pancreas. Arch Surg 132:771–776PubMedGoogle Scholar
  79. 79.
    Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL (1996) Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 224:463–473PubMedGoogle Scholar
  80. 80.
    Phan GQ, Yeo CJ, Cameron JL, Maher MM, Hruban RH, Udelsman R (1997) Pancreaticoduodenectomy for selected periampullary neuroendocrine tumors: fifty patients. Surgery 122:989–996PubMedGoogle Scholar
  81. 81.
    Talamini MA, Moesinger RC, Pitt HA, Sohn TA, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL (1997) Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg 225:590–599CrossRefPubMedGoogle Scholar
  82. 82.
    Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Lillemoe KD, Pitt HA (1998) Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 227:821–831CrossRefPubMedGoogle Scholar
  83. 83.
    Fink AS, DeSouza LR, Mayer EA, Hawkins R, Longmire WP Jr (1988) Long-term evaluation of pylorus preservation during pancreaticoduodenectomy. World J Surg 12:663–670PubMedGoogle Scholar
  84. 84.
    Huang JJ, Yeo CJ, Sohn TA, Lillemoe KD, Sauter PK, Coleman J, Hruban RH, Cameron JL (2000) Quality of life and outcomes after pancreaticoduodenectomy. Ann Surg 231:890–898CrossRefPubMedGoogle Scholar
  85. 85.
    Kokoska ER, Stapleton DR, Virgo KS, Johnson FE, Wade TP (1998) Quality of life measurements do not support palliative pancreatic cancer treatments. Int J Oncol 13:1323–1329PubMedGoogle Scholar
  86. 86.
    McLeod RS, Taylor BR, O’Connor BI, Greenberg GR, Jeejeebhoy KN, Royall D, Langer B (1995) Quality of life, nutritional status, and gastrointestinal hormone profile following the Whipple procedure. Am J Surg 169:179–185CrossRefPubMedGoogle Scholar
  87. 87.
    Patel AG, Toyama MT, Kusske AM, Alexander P, Ashley SW, Reber HA (1995) Pylorus-preserving Whipple resection for pancreatic cancer. Is it any better? Arch Surg 130:838–842PubMedGoogle Scholar
  88. 88.
    Patti MG, Pellegrini CA, Way LW (1987) Gastric emptying and small bowel transit of solid food after pylorus-preserving pancreaticoduodenectomy. Arch Surg 122:528–532PubMedGoogle Scholar
  89. 89.
    Yeo CJ, Cameron JL, Lillemoe KD, Sohn TA, Campbell KA, Sauter PK, Coleman J, Abrams RA, Hruban RH (2002) Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. Part 2. Randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 236:355–366CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • H. G. Smeenk
    • 1
  • T. C. K. Tran
    • 1
  • J. Erdmann
    • 1
  • C. H. J. van Eijck
    • 1
  • J. Jeekel
    • 1
    Email author
  1. 1.Department of General SurgeryErasmus Medical CentreRotterdamThe Netherlands

Personalised recommendations